[Clinical observation of palitaxel in the treatment of gynecologic malignant tumors].

OBJECTIVE

To observe the therapeutic effect of palitaxel.

METHODS

Of 37 cases, 33 were treated when tumor recurrence occurred after surgery or chemotherapy. There were 27 cases with ovarian cancer, 6 with fallopian tube cancer. 3 with cervix cancer, and 1 with endometrium cancer. In all cases, diagnosis was confirmed by histopathology. Palitaxel (135-150 mg/m2) was administered i.v. or i.p. once every three werks in combination with cisplatin (PDD) 60 mg/m2 and cyclophosphamide (CTX) 60 mg/d. Antihistaminics and antiemetic were given prior to palitaxel. The results of treatment were compared with those in 37 cases treated in the some time period with PAC or VBP regimen.

RESULTS

The overall median survival time of the control group was 4 months, and 8.5 months in the palitaxel treated group (P < 0.001). The response rate was 18.9% and 48.6% respectively (P < 0.005). The major toxic effects was myelosuppression and alopecia.

CONCLUSION

Palitaxel is effective in the treatment of advanced gynecological tumors.